J Gastroenterology: Calcium channel blockers improve outcomes in patients after resection of intrahepatic cholangiocarcinoma

Intrahepatic cholangiocarcinoma (ICC) is the second most common subtype of primary liver cancer worldwide, with a high incidence in East and Southeast As.

To this end, we retrospectively evaluated 79 patients diagnosed with intrahepatic cholangiocarcinoma by hepatectomy between January 2002 and May 201 The prognosis and time to recurrence were then compared between patients treated with calcium channel blockers (CCBs) (n=29) and those not treated with CCBs (n=5

The results showed that in the original and matched cohorts, overall survival and recurrence-free survival in the CCBs group were significantly longer than those in the non-CCBs group (98 months vs 45 months, p=010; 96 months vs 22 months) month, p=02

This study confirms that CCBs have multiple antitumor effects in addition to their well-known blood pressure-lowering effects, such as CCBs treatment may improve the prognosis of patients with intrahepatic cholangiocarcino.

Original source:

Kenichiro Koda.